{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:35Z","timestamp":1790856395249,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10549-025-07853-w","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:51:50Z","timestamp":1764226310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer"],"prefix":"10.1007","volume":"215","author":[{"given":"Sophia","family":"Zelizer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace B.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat","family":"Chandarlapaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Z.","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"6","key":"7853_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327\u2013344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"7853_CR2","doi-asserted-by":"publisher","first-page":"13726","DOI":"10.3390\/ijms241813726","volume":"24","author":"C Mark","year":"2023","unstructured":"Mark C, Lee JS, Cui X, Yuan Y (2023) Antibody-Drug conjugates in breast cancer: current status and future directions. IJMS 24(18):13726. https:\/\/doi.org\/10.3390\/ijms241813726","journal-title":"IJMS"},{"issue":"1","key":"7853_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J (2020) Antibody-drug conjugates: a comprehensive review. Mol Cancer Res 18(1):3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0582","journal-title":"Mol Cancer Res"},{"issue":"1","key":"7853_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y et al (2024) A review of the clinical efficacy of FDA-approved antibody-drug conjugates in human cancers. Mol Cancer 23(1):62. https:\/\/doi.org\/10.1186\/s12943-024-01963-7","journal-title":"Mol Cancer"},{"issue":"1","key":"7853_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"7853_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/BCTT.S245024","volume":"13","author":"AS Linehan","year":"2021","unstructured":"Linehan AS, Fitzpatrick OM, Morris PG (2021) Profile of Trastuzumab Deruxtecan in the management of patients with HER2-positive unresectable or metastatic breast cancer: an evidence-based review. BCTT 13:151\u2013159. https:\/\/doi.org\/10.2147\/BCTT.S245024","journal-title":"BCTT"},{"issue":"5","key":"7853_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102924","volume":"9","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V et al (2024) Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open 9(5):102924. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102924","journal-title":"ESMO Open"},{"key":"7853_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","author":"S Tolaney","year":"2025","unstructured":"Tolaney S, Zefei J, Zhang Q, Barroso-Sousa R, Park Y, Rimawi M et al (2025) Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): interim results from DESTINY-Breast09. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA1008","journal-title":"J Clin Oncol."},{"issue":"4","key":"7853_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/cancers15041130","volume":"15","author":"L Guidi","year":"2023","unstructured":"Guidi L, Pellizzari G, Tarantino P, Valenza C, Curigliano G (2023) Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges. Cancers 15(4):1130. https:\/\/doi.org\/10.3390\/cancers15041130","journal-title":"Cancers"},{"key":"7853_CR10","doi-asserted-by":"crossref","unstructured":"Das G, Vasquez M, Zhang J, Lee JH, Gao Y, Zhang J et al (2024) Spatial omics analysis uncovers microenvironmental remodeling and immune dynamics in T-DXd resistant metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium (SABCS); 2024; San Antonio, TX. Abstract PS4\u201309","DOI":"10.1158\/1557-3265.SABCS24-PS4-09"},{"issue":"5","key":"7853_CR11","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","volume":"10","author":"J Tsurutani","year":"2020","unstructured":"Tsurutani J, Iwata H, Krop I, J\u00e4nne PA, Doi T, Takahashi S et al (2020) Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov 10(5):688\u2013701. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1014","journal-title":"Cancer Discov"},{"issue":"10","key":"7853_CR12","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3390\/cancers15102664","volume":"15","author":"Y Hou","year":"2023","unstructured":"Hou Y, Nitta H, Li Z (2023) HER2 intratumoral heterogeneity in breast cancer, an evolving concept. Cancers 15(10):2664. https:\/\/doi.org\/10.3390\/cancers15102664","journal-title":"Cancers"},{"issue":"2","key":"7853_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-024-07367-x","volume":"207","author":"A Isogai","year":"2024","unstructured":"Isogai A, Nozawa K, Nakakami A, Komaki R, Ozaki Y, Endo Y et al (2024) Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: a single-institution retrospective observational study. Breast Cancer Res Treat 207(2):253\u2013261. https:\/\/doi.org\/10.1007\/s10549-024-07367-x","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"7853_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101792","volume":"5","author":"A Gupta","year":"2024","unstructured":"Gupta A, Michelini F, Shao H, Yeh C, Drago JZ, Liu D, Rosiek E, Romin Y, Ghafourian N, Thyparambil S, Misale S, Park W, de Stanchina E, Janjigian YY, Yaeger R, Li BT, Chandarlapaty S (2024) EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med 5(11):101792. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101792","journal-title":"Cell Rep Med"},{"issue":"8","key":"7853_CR15","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y et al (2023) Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med 29(8):2110\u20132120. https:\/\/doi.org\/10.1038\/s41591-023-02478-2","journal-title":"Nat Med"},{"key":"7853_CR16","doi-asserted-by":"crossref","unstructured":"Chen W, Gupta A, Mai N, Lau J, Singh S, Chodera J et al (2025) Resistance to Trastuzumab Deruxtecan (T-DXd) in breast cancer via loss of HER2 expression. Poster session presented at: American Association for Cancer Research (AACR); 2025; Chicago, IL","DOI":"10.1158\/1538-7445.AM2025-LB280"},{"issue":"7","key":"7853_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382(7):610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"issue":"12","key":"7853_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R et al (2022) Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 386(12):1143\u20131154. https:\/\/doi.org\/10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"issue":"4","key":"7853_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189369","volume":"1180","author":"R Madej","year":"2025","unstructured":"Madej R, Meluch M, Puskulluglu M (2025) Sequencing of antibody drug conjugates in breast cancer: evidence gap and future directions. BBA Rev Cancer 1180(4):189369. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189369","journal-title":"BBA Rev Cancer"},{"key":"7853_CR20","unstructured":"Metzger O, Mandrekar S, DeMichele A, Gianni L, Gligorov J, Lim E et al (2024) AFT-38 PATINA: a randomized, open label, phase III trial to evaluate the efficacy and safety of Palbociclib + Anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor-positive (HR+)\/HER2-positive metastatic breast cancer [abstract]. Presented at: San Antonio Breast Cancer Symposium (SABCS); 2024; San Antonio, TX. Available from: https:\/\/sabcs.org\/Portals\/0\/Documents\/PATINA_Abstract_12-11-24.pdf?ver=6NaxdWhjPHoc7aD3kzrO4Q%3D%3D"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07853-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07853-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07853-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:38:56Z","timestamp":1767789536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07853-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7853"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07853-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JZD has received institutional grants\/funding from Merck, AstraZeneca, Bolt Therapeutics, Jazz Pharmaceutics, and Orum therapeutics and has performed consulting\/advisory work for AstraZeneca, Genagon, AmMax Bio, NuProbe, Revelio Therapeutics, MEDACorp, and BAIRD conferences. SC has received institutional grants\/funding from Daiichi-Sankyo and AstraZeneca, share options in Totus Medicines, and consultation\/Ad board\/Honoraria from Daiichi-Sankyo, AstraZeneca, Lilly, Casdin Capital, and Pathos AI. CD has performed consulting\/advisory work for Pfizer, Novartis, and Daiichi-Sankyo. SM has received institutional grants\/funding from Duality, Biontech, Avacta, Genentech, Daiichi-Sankyo, AstraZeneca, Pfizer, Seagen, D3 Bio and Nuvanation, and consultation\/Ad board\/Honoraria from Genentech, Daiichi-Sankyo, AstraZeneca, Pfizer, Gilead, Boehringer, Avacta, and Biontech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The MSK Institutional Review Board on Human Research approved the study. This study complied with all relevant ethical regulations regarding patient data, in line with ethical norms and standards in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"19"}}